Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind placebo-controlled booster trial of pGX9501 DNA COVID-19 vaccine after prior inactivated vaccination
ChiCTR2100049744Phase 2Completed
- Sponsor
- Sichuan Provincial Center for Disease Control and Prevention
- Start
- Dec 2021
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of INO-4800 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Sichuan Provincial Center for Disease Control and Prevention. Primary endpoints: Geometric mean titer of binding antibody against SARS-CoV-2 S protein by ELISA, Geometric mean titer of neutralizing antibody against SARS-CoV-2 S protein by serum neutralization assay and 7 more. Started Dec 2021; status: completed.
02
Drugs
INO-4800
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100049744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049744.